Acetyl Tetrapeptide-5

From a microscopic molecular perspective, the core pathological mechanisms behind periocular puffiness and edematous eye bags involve abnormally elevated permeability of periocular capillaries, disrupted local microcirculation and abnormal interstitial fluid retention. Angiotensin-converting enzyme 1 (ACE-1) serves as the core target governing these physiological processes. ACE-1 is abundantly expressed in microvascular endothelial cells of human skin. Overactivated ACE-1 catalyzes the conversion of angiotensin I to angiotensin II, which directly acts on microvascular smooth muscle cells and triggers dysregulated vasoconstriction as well as widened gaps between endothelial cells.

This drastically increases vascular permeability, allowing water, electrolytes and trace proteins in blood to leak into surrounding interstitial tissues and eventually induce interstitial fluid accumulation, puffiness and eye bags around the eyes.

Acetyl tetrapeptide-5 exhibits specific binding affinity toward the active catalytic site of ACE-1. Its small-molecule peptide structure precisely inserts into the catalytic pocket of ACE-1 and blocks substrate binding via steric hindrance, potently suppressing ACE-1 enzymatic activity and halting angiotensin II production at the source.

Within the molecular regulatory cascade, ACE-1 inhibition by it bidirectionally restores the periocular microcirculatory system. On one hand, suppressing angiotensin II production stabilizes vasoconstriction rhythm of microvascular smooth muscle, repairs damaged vascular endothelial barriers and narrows endothelial gaps to drastically reduce abnormal capillary leakage and sustained interstitial fluid exudation and buildup. On the other hand, the molecule indirectly boosts the activity of lymphatic endothelial cells to accelerate lymphatic circulation and metabolism around the eyes, facilitating rapid drainage of excess trapped fluid and metabolic waste in interstitial tissues to relieve periocular edema.

Conventional anti-puffiness ingredients only deliver short-term fluid metabolism improvements, whereas it relies on long-term target inhibition to sustain stable vascular permeability and optimize the fundamental state of periocular microcirculation, fundamentally lowering recurring edematous eye bags. Clinical test data verifies that two consecutive weeks of skincare product application containing this ingredient yields significant relief of periocular puffiness.

Skin glycation represents a core microscopic trigger of periocular fine lines, sagging and dull aging, with the generation and accumulation of advanced glycation end products (AGEs) as the key molecular target. Periocular skin is the thinnest skin layer in the human body with abundant collagen yet lacks sebaceous gland protection, rendering it highly susceptible to glycation reactions. Reducing sugars generated from human metabolism undergo non-enzymatic glycation with structural proteins such as collagen and elastin in skin to gradually form AGEs.

AGEs form molecular cross-links with structural proteins, causing stiffening, fragmentation and loss of collagen fibers alongside diminished elastin activity.This ultimately results in loss of skin elasticity, ptosis, proliferation of fine lines, dull yellow discoloration and aggravated periocular aging driven by AGE buildup.

Acetyl tetrapeptide-5 targets and blocks glycation progression while eliminating aging damage through dual molecular mechanisms. First, the peptide competitively binds to active glycation sites, encapsulating free reducing sugars and skin structural proteins to block their non-specific interaction, suppress AGE formation at the root and prevent cross-linking damage to collagen and elastin.

Second, for minor pre-existing AGEs in skin, it weakens binding affinity between AGEs and structural proteins via molecular dissociation, accelerating breakdown and excretion of aging metabolites to cut down AGE accumulation in periocular skin.

Meanwhile, the ingredient modulates signaling pathways to stimulate fibroblast activity and boost de novo synthesis of collagen and elastin. It repairs glycation-impaired dermal fiber architecture, rebuilds supportive structure of periocular skin, mitigates sagging and fine lines, and delays periocular skin aging.

The periocular skin barrier is inherently fragile. Chronic microcirculatory disorders, glycation damage and external irritants compromise stratum corneum structure and weaken barrier function, triggering dryness, sensitivity and fragility. Damaged skin barriers in turn worsen puffiness, aging and pigmentation, creating a vicious cycle. It remodels the structure and function of the periocular skin barrier via microscopic molecular repair mechanisms.

The ingredient regulates keratinocyte proliferation and differentiation, enhances lipid synthesis and ordered arrangement within the stratum corneum, repairs compromised defensive layers of the epidermis, reduces transepidermal water loss and reinforces skin moisturizing capacity. Its potent anti-inflammatory and soothing molecular activity neutralizes excess skin free radicals, alleviates mild periocular inflammatory stress, minimizes irritative damage from environmental stressors and elevates inherent skin tolerance and self-repair capacity. It establishes a stable defensive system for periocular skin to sustain the skincare benefits of de-puffing, anti-aging and pigment fading.